Nøhr, Anne Krogh
Forsingdal, Annika http://orcid.org/0000-0001-9480-4365
Moltke, Ida
Howes, Oliver D.
Vitezic, Morana
Albrechtsen, Anders
Dalby, Maria http://orcid.org/0000-0001-6018-3468
Funding for this research was provided by:
Innovationsfonden (8053-00004A)
RCUK | Medical Research Council (MC_A656_5QD30_2135)
Maudsley Charity (666)
Wellcome Trust (094849/Z/10/Z)
Novo Nordisk Fonden (NNF20OC0061343)
Article History
Received: 1 June 2022
Revised: 5 October 2022
Accepted: 13 October 2022
First Online: 29 October 2022
Competing interests
: The trials were conducted in collaboration between Takeda Pharmaceutical Company, Ltd. and H. Lundbeck A/S. AKN, AF, MV, and MD are employed by H. Lundbeck A/S. OH is a part-time employee and stockholder of H. Lundbeck A/S. OH has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche and Viatris/ Mylan. OH has a patent for the use of dopaminergic imaging.